These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 21897890)

  • 1. Intensifying existing premix therapy (BIAsp 30) with BIAsp 50 and BIAsp 70: A consensus statement.
    Brito M; Ligthelm RJ; Boemi M; Kumar A; Raz I; Koblik T; Gao Y; Christiansen JS
    Indian J Endocrinol Metab; 2011 Jul; 15(3):152-60. PubMed ID: 21897890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical guidance on intensification of insulin therapy with BIAsp 30: a consensus statement.
    Unnikrishnan AG; Tibaldi J; Hadley-Brown M; Krentz AJ; Ligthelm R; Damci T; Gumprecht J; Gero L; Mu Y; Raz I
    Int J Clin Pract; 2009 Nov; 63(11):1571-7. PubMed ID: 19780866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consensus on Initiation and Intensification of Premix Insulin in Type 2 Diabetes Management.
    Mohan V; Kalra S; Kesavadev J; Singh AK; Kumar A; Unnikrishnan AG; Chawla R; Mukherjee JJ; Sahay RK; Kumar JS; Bhoraskar A; Asirvatham AJ; Panda JK; Zargar AH; Das AK
    J Assoc Physicians India; 2017 Apr; 65(4):59-73. PubMed ID: 28527166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 32-Week Randomized Comparison of Stepwise Insulin Intensification of Biphasic Insulin Aspart (BIAsp 30) Versus Basal-Bolus Therapy in Insulin-Naïve Patients with Type 2 Diabetes.
    Linjawi S; Lee BW; Tabak Ö; Lövdahl S; Werther S; Abusnana S
    Diabetes Ther; 2018 Feb; 9(1):1-11. PubMed ID: 29129018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes.
    Valensi P
    Diabetes Metab Syndr Obes; 2009 Jun; 2():61-71. PubMed ID: 21437119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs.
    Yang W; Ji Q; Zhu D; Yang J; Chen L; Liu Z; Yu D; Yan L
    Diabetes Care; 2008 May; 31(5):852-6. PubMed ID: 18268073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial.
    Rosenstock J; Emral R; Sauque-Reyna L; Mohan V; Trescolí C; Al Sifri S; Lalic N; Alvarez A; Picard P; Bonnemaire M; Demil N; McCrimmon RJ;
    Diabetes Care; 2021 Jun; 44(10):2361-70. PubMed ID: 34183429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical Guidance on the Use of Premix Insulin Analogs in Initiating, Intensifying, or Switching Insulin Regimens in Type 2 Diabetes.
    Wu T; Betty B; Downie M; Khanolkar M; Kilov G; Orr-Walker B; Senator G; Fulcher G
    Diabetes Ther; 2015 Sep; 6(3):273-87. PubMed ID: 26104878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK.
    McCrimmon RJ; Palmer K; Alsaleh AJO; Lew E; Puttanna A
    Diabetes Ther; 2022 Jun; 13(6):1203-1214. PubMed ID: 35543869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensification of IDegAsp Twice Daily (Adding Insulin Aspart vs. Switching To Basal-Bolus): Exploratory Randomized Trial in Type 2 Diabetes.
    Bebakar WM; Chaykin L; Hersløv ML; Rasmussen S
    Diabetes Ther; 2017 Feb; 8(1):197-205. PubMed ID: 27853981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
    Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
    Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes.
    Liebl A; Mohan V; Yang W; Strojek K; Linjawi S
    Drugs R D; 2018 Mar; 18(1):27-39. PubMed ID: 29468559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensifying insulin therapy in type 2 diabetes mellitus: dosing options for insulin analogue premixes.
    Tibaldi JM
    Clin Ther; 2011 Nov; 33(11):1630-42. PubMed ID: 22030443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes.
    Dashora U; Ashwell SG; Home PD
    Diabetes Obes Metab; 2009 Jul; 11(7):680-7. PubMed ID: 19527481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
    Clements MR; Tits J; Kinsley BT; Råstam J; Friberg HH; Ligthelm RJ
    Diabetes Obes Metab; 2008 Mar; 10(3):229-37. PubMed ID: 18269638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings.
    Liebl A; Prusty V; Valensi P; Kawamori R; Christiansen JS; Palmer AJ; Balschmidt P; Ligthelm R; Mohan V
    Drugs; 2012 Jul; 72(11):1495-520. PubMed ID: 22818015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US.
    Shao H; Alsaleh AJO; Dex T; Lew E; Fonseca V
    Diabetes Ther; 2022 Sep; 13(9):1659-1670. PubMed ID: 35930188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biphasic insulin aspart 30: literature review of adverse events associated with treatment.
    Davidson J; Vexiau P; Cucinotta D; Vaz J; Kawamori R
    Clin Ther; 2005; 27 Suppl B():S75-88. PubMed ID: 16519039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of IDegAsp Versus BIAsp 30, Both Twice Daily, in Elderly Patients with Type 2 Diabetes: Post Hoc Analysis of Two Phase 3 Randomized Controlled BOOST Trials.
    Fulcher G; Mehta R; Fita EG; Ekelund M; Bain SC
    Diabetes Ther; 2019 Feb; 10(1):107-118. PubMed ID: 30474818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biphasic insulin aspart 30/70: pharmacokinetics and pharmacodynamics compared with once-daily biphasic human insulin and Basal-bolus therapy.
    Heise T; Heinemann L; Hövelmann U; Brauns B; Nosek L; Haahr HL; Olsen KJ
    Diabetes Care; 2009 Aug; 32(8):1431-3. PubMed ID: 19487640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.